BridgeBio stock holds Buy rating, price target at $56 - H.C. Wainwright

On Monday, BridgeBio Pharma (NASDAQ:BBIO) maintained a positive outlook from H.C. Wainwright, with the firm reiterating a Buy rating and increasing the price target to $56.00 from the previous $53.00. The stock has shown strong momentum, gaining nearly 9% in the past week and trading near its 52-week high of $39.67. The adjustment reflects an optimistic view on the company’s financial prospects, with revised revenue forecasts for the upcoming years. According to InvestingPro data, the company maintains a healthy financial position with a current ratio of 4.57, indicating strong liquidity.

BridgeBio’s ATTRUBY, a treatment for adults with ATTR-CM, was approved by the FDA in late 2024 and remains the only product in the United States with a label specifying near-complete stabilization of transthyretin (TTR). ATTRUBY, also known as acoramidis, has shown a positive sales trajectory, with 2,072 unique patient prescriptions by 756 physicians reported as of late April 2025. The company’s impressive gross profit margin of 95.35% demonstrates strong pricing power in its pharmaceutical portfolio.

Acoramidis is differentiated in the market as a selective small molecule, orally administered therapy that achieves at least 90% stabilization of TTR. This mechanism of action is significant as it is the sole disease-modifying treatment that provides such a high level of TTR stabilization, which has been shown to improve clinical outcomes for patients with both variant and wild-type ATTR-CM.

The updated price target from H.C. Wainwright is based on revised revenue ramp projections. Analysts now anticipate BridgeBio’s full-year 2025 revenue to reach approximately $423.2 million, with expectations for a further increase to $637.2 million in 2026. These figures are a significant jump from the previous forecasts of $188 million for 2025 and $497.2 million for 2026.

The firm’s reiteration of the Buy rating and the price target increase are based on BridgeBio’s current sales momentum and the unique positioning of acoramidis in the treatment landscape for ATTR-CM. With a market capitalization of $7.33 billion and strong analyst consensus, BridgeBio shows promising potential despite current overvaluation according to InvestingPro Fair Value metrics. Discover comprehensive analysis and 10+ additional ProTips for BBIO in the exclusive Pro Research Report, available with your InvestingPro subscription.

In other recent news, BridgeBio Pharma has reported notable developments in its financial and clinical activities. Scotiabank (TSX:BNS) analyst Greg Harrison raised the price target for BridgeBio Pharma to $55, citing strong first-quarter results for 2025, with net revenue from Attruby reaching $36.7 million, significantly surpassing both Scotiabank’s and consensus estimates. BMO Capital also adjusted its price target for BridgeBio Pharma to $42, reflecting updated expectations for the company’s US sales performance in the second quarter of 2025, with anticipated revenues exceeding consensus estimates by 20% to 40%.

Piper Sandler reiterated its Overweight rating for BridgeBio Pharma, maintaining a price target of $63, and highlighted the potential market impact of the CALIBRATE study for the drug encaleret. The study’s results are expected in the second half of 2025, focusing on its use in treating autosomal dominant hypocalcemia type 1. Meanwhile, BridgeBio Pharma has launched the ACT-EARLY clinical trial, a landmark study testing acoramidis as a preventative treatment for transthyretin amyloid disease (ATTR).

The company also shared promising findings from the ATTRibute-CM Phase 3 trial, demonstrating that acoramidis significantly improves survival rates in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). These results, published in the Journal of the American College of Cardiology, underscore the drug’s efficacy and potential impact on clinical practice. BridgeBio Pharma continues to advance its portfolio and address unmet needs in genetic diseases, with ongoing trials and strong commercial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.